Zofran and Cleft Palate
A 2012 study of pregnant women with morning sickness found a higher incidence of babies being born with a cleft palate if their mothers used ondansetron, the active ingredient in Zofran. Mothers with concerns can request a FREE consultation. Read more about a lawsuit for a baby with a cleft palate from Zofran.
Drug Safety Communication
On June 29, 2012, the FDA warned the public that a 32 mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) may affect the electrical activity of the heart (QT interval prolongation), which could pre-dispose patients to develop an abnormal and potentially fatal heart rhythm known as Torsades de Pointes.
On September 15, 2011, the FDA informed the public that ondansetron, the active ingredient in Zofran, may increase the risk of developing abnormal changes in the electrical activity of the heart, which can result in a potentially fatal abnormal heart rhythm.
On March 27, 2014, GlaxoSmithKline announced a recall of alli® weight loss products from U.S. and Puerto Rico retailers because it believed that some of the packages of the product were tampered with. This was based on inquiries from consumers in seven states about bottles of alli® that contained tablets and capsules that were not alli®. These tampered products were purchased in retail stores. Please note, that this recall is over and no longer applies to alli® available in retail stores.